Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-25 Exercise | 2024-04-25 4:55 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 3,730,672 | $0 | 5,176,222 (Indirect) | View |
| 2024-02-15 Option Award | 2024-02-20 9:21 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 400 | $9.82 | 746,907 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-05 5:29 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 40,000 | $0 | 40,000 (Direct) | View |
Ownership | 2024-02-05 5:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 0 | $0 | 477,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:31 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 277,750 | $0 | 277,750 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:27 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 70,000 | $0 | 70,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:23 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 63,000 | $0 | 63,000 (Direct) | View |
| 2023-12-29 Other | 2023-12-29 5:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,841,518 | $0 | 5,485,719 (Indirect) | View |
| 2023-12-22 Option Award | 2023-12-22 6:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 134,953 | $0 | 134,953 (Direct) | View |
| 2023-12-07 Option Award | 2023-12-11 5:41 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 16,667 | $600 | 16,667 (Indirect) | View |
| 2023-11-22 Option Award(A) | 2023-12-08 4:07 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 50,000 | $0 | 84,360 (Direct) | View |
| 2023-11-24 Conversion(A) | 2023-12-08 4:07 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 35,219 | $0 | 84,360 (Indirect) | View |
Ownership(A) | 2023-12-08 4:03 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 0 | $0 | 34,360 (Indirect) | View |
| 2023-11-24 Conversion | 2023-11-28 4:05 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,521,367 | $0 | 4,250,938 (Indirect) | View |
| 2023-11-22 Option Award | 2023-11-27 4:36 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Albers Jeffrey W. Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-11-22 Option Award | 2023-11-27 4:33 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Stelzer Laurie Director | 50,000 | $0 | 50,000 (Direct) | View |
| 2023-11-22 Option Award | 2023-11-27 4:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 374,000 | $0 | 1,120,507 (Direct) | View |
| 2023-11-24 Conversion | 2023-11-27 4:25 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 741,526 | $0 | 1,120,507 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-05 4:15 pm | N/A 2033-09-01 | Aeglea BioTherapeutics Inc. | AGLE | King-Jones Heidy See Remarks | 13,495,255 | $0 | 13,495,255 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-05 4:10 pm | N/A 2033-09-01 | Aeglea BioTherapeutics Inc. | AGLE | Burrows Scott L Chief Financial Officer | 10,121,441 | $0 | 10,121,441 (Direct) | View |
Ownership | 2023-06-30 5:32 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 536,284,540 (Indirect) | View |
Ownership | 2023-06-30 5:14 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Turtle Cameron Chief Operating Officer | 0 | $0 | 65,959,896 (Direct) | View |
Ownership | 2023-06-30 5:13 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | HENDERSON MICHAEL THOMAS Director | 0 | $0 | 1,950,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-30 4:34 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan President and CFO | 19,787,969 | $0 | 19,787,969 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-30 4:33 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | Cox Russell J. Director | 1,950,000 | $0 | 1,950,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-30 4:32 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | Magovcevic-Liebisch Ivana Director | 1,950,000 | $0 | 1,950,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-30 4:31 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | Smith Hunter C Director | 1,950,000 | $0 | 1,950,000 (Direct) | View |
| 2023-06-22 Option Award | 2023-06-30 4:30 pm | N/A 2033-06-22 | Aeglea BioTherapeutics Inc. | AGLE | Lawton Alison Frances Director | 1,950,000 | $0 | 1,950,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:25 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 550,000 | $0 | 550,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:24 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul General Counsel | 500,000 | $0 | 500,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:22 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Business Officer | 500,000 | $0 | 500,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:20 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 640,000 | $0 | 640,000 (Direct) | View |
| 2022-11-14 Option Award | 2023-01-27 6:20 pm | N/A 2032-11-13 | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 25,000 | $0 | 25,000 (Direct) | View |
Ownership | 2023-01-27 6:18 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 0 | $0 | 140,250 (Direct) | View |
| 2022-11-29 Option Award | 2022-12-01 8:47 pm | N/A 2032-11-28 | Aeglea BioTherapeutics Inc. | AGLE | Goldberg Jeff Marc President and CEO | 1,884,838 | $0 | 1,884,838 (Direct) | View |
| 2022-08-23 Option Award | 2022-08-25 7:39 pm | N/A 2032-08-22 | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel | 130,000 | $0 | 130,000 (Direct) | View |
Ownership | 2022-08-25 7:37 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel | 0 | $0 | 219,000 (Direct) | View |